Molecular drivers and emerging treatments in anaplastic thyroid cancer (2025)

Compuscript LtdApr 20 2025

At the core of ATC's pathogenesis are genetic aberrations, with prominent alterations in MAPK and PI3K-AKT-mTOR signaling pathways. These dysregulated pathways promote unchecked cellular proliferation, survival, and metastasis. Mutations in genes such as BRAF, RAS, PIK3CA, TP53, and TERT have emerged as key drivers of ATC development and progression. Understanding the interplay between these mutations has enabled refined subclassifications of ATC, potentially informing personalized therapeutic approaches.

The review emphasizes the significance of targeted therapies, especially BRAF and MEK inhibitors, in improving patient outcomes. In particular, dual inhibition strategies have demonstrated efficacy in shrinking tumors and enabling surgical interventions. While trimodal therapy—a combination of surgery, chemotherapy, and radiation—remains the cornerstone for localized disease, its limitations in advanced ATC highlight the need for additional therapeutic avenues.

Immunotherapy has gained traction as a complementary modality. The tumor microenvironment of ATC, marked by immune cell infiltration and PD-L1 overexpression, presents opportunities for immune checkpoint inhibitors. However, response rates remain variable, and research is ongoing to optimize patient selection and treatment combinations.

Diagnostic innovations are also covered in detail, including the comparative efficacy of fine needle aspiration (FNA) versus core needle biopsy (CNB) and the utility of 18F-FDG PET/CT imaging in staging and treatment planning. Advances in immunohistochemical markers and liquid biopsies hold promise for earlier detection and real-time monitoring of therapeutic response.

The article concludes by highlighting the emerging role of mitochondrial metabolism as a therapeutic target and the potential of novel agents, including nanoparticles and oncolytic viruses, to enhance radioiodine uptake and overcome therapeutic resistance.

Source:

Journal reference:

Zou, Z., & Zhong, L. (2024). Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & Diseases. doi.org/10.1016/j.gendis.2024.101403.

Comments (0)

Study identifies a new key factor contributing to aggressive nature of pancreatic cancer

Radiation from CT scans linked to future cancer risks in children and adults

New study connects parasitic disease to genetic changes in the cervical lining

Inherited genetic variants play crucial role in cancer development and behavior

Genetic diversity of malaria parasite challenges one size fits all strategies

Breakthrough in chicken genomics offers hope against avian influenza

Metabolic syndrome found to increase risk of breast cancer recurrence and death

New blood test method improves accuracy of cancer detection

Quirky Comment Title

Post